Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 21, 2013. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,423,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,587 pence per share; lowest price paid was 1,575.50 pence per share.
- Treasury Holdings (Settled): 501,669,912 shares, representing 9.35% of total issued share capital.
- Treasury Holdings (Including Unsettled): 505,941,912 shares, representing 10.40% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,865,967,603 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,423,000 shares on October 21, 2013. Consequently, the percentage of shares held in Treasury increased to 9.35% of issued capital (or 10.40% of voting rights when including unsettled trades).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of specific risks and contingencies. It is a compliance announcement confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (501,669,912 settled) against the company's latest capitalization table.
- Confirm the denominator for voting rights calculations is 4,865,967,603 shares (excluding treasury shares).
- Check if the 10.40% voting rights held in Treasury impacts any shareholder notification thresholds under Disclosure and Transparency Rules.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or interim results for revenue and profit metrics.